Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, Fresh and Is Redirecting to New Developments

Quantum Genomics Société Anonyme announces that efficacy results for firibastat in its phase III study FRESH, are non-significant versus placebo. These results will be presented in detail at the AHA congress.